A Phase 1b, Open-Label, Dose Escalation, Multi-arm Study of MLN4924 Plus Docetaxel, Gemcitabine, or Combination of Carboplatin and Paclitaxel in Patients With Solid Tumors

Name: A Phase 1b, Open-Label, Dose Escalation, Multi-arm Study of MLN4924 Plus Docetaxel, Gemcitabine, or Combination of Carboplatin and Paclitaxel in Patients With Solid Tumors
Creator: Vivli
Published: 2025-10-01 20:54:03
License: 暂无描述

DataCite Commons2025-10-01 更新2026-05-07 收录

下载链接：

https://search.vivli.org/doiLanding/studies/PR00008400/isLanding

下载链接

链接失效反馈

官方服务：

资源简介：

The purpose of this study is to establish the maximum tolerated dose (MTD) and assess the safety and tolerability of MLN4924 (pevonedistat) in combination with docetaxel, paclitaxel and carboplatin, and gemcitabine in participants with solid tumors.

提供机构：

Vivli

创建时间：

2022-08-29